CBG and Lupus: What the Research Actually Shows (2026)

Updated October 26, 2026. Written by Jaime Alefosio, Board Certified Exponential Health Coach (ANMCB) · Founder, Hey Mary Jane Published: August 26, 2025

CBG is one of the more interesting cannabinoids in autoimmune research. Laboratory studies show it dampening specific inflammatory signals in human immune cells without broadly suppressing immune function, which is unusual and worth paying attention to. What does not yet exist is a study in lupus specifically. The mechanism is promising and the question is still open.

If you searched for a CBG lupus study, you were looking for something concrete. The honest answer is more interesting than a yes or a no.

There is real science here. It is just not the science most pages imply, and knowing the difference changes what you do with it.

Here is what CBG has been shown to do, in what kind of study, how close any of it comes to lupus, and what a reasonable person should take from that.

The endocannabinoid system is a cell-signalling network spanning the brain, gut, immune tissue, and peripheral nerves that helps regulate sleep, stress response, pain perception, and immune activity. Cannabinoids interact with this network, though each one behaves differently.

What pulled CBG into inflammation research is how it appears to act. A 2026 review in Frontiers in Pharmacology from Benemérita Universidad Autónoma de Puebla, written around drug-resistant epilepsy, summarises the wider immune picture this way:

In plain terms: in the laboratory, CBG appears to quiet inflammatory signals that have been switched on, while leaving baseline immune function largely alone. That selectivity is the reason researchers keep returning to it, because broad immunosuppression is the trade-off that makes conventional autoimmune therapy difficult to live with.

One caveat on that sentence. The review is summarising Fleisher-Berkovich et al., which is also cited further down this page. They are not two independent findings. They are a review and the cell study underneath it.

That is a mechanism worth understanding. It is not yet a finding about people with lupus.

Four bodies of work carry the weight, and it is worth being precise about what kind of study each one is.

The Duesseldorf work is the closest to a person: human cells, an autoimmune condition, CBG itself. Its authors are careful about where that leaves things. Minor cannabinoids have shown anti-inflammatory properties in the laboratory but, in their words, due to the lack of studies, they are not widely used. Their conclusion is framed as grounds for further research.

Not yet. A PubMed search for cannabigerol and lupus returns no published studies as of 2026.

That is worth stating plainly, because a good deal of writing on this topic implies otherwise. It also is not the dead end it might sound like.

What it means: the specific study has not been run. It has not been run and failed. It simply has not been run. Every claim you read about CBG for lupus is an extrapolation from other autoimmune conditions, from other cannabinoids, or from cell cultures.

Why the extrapolation is not unreasonable: lupus, rheumatoid arthritis, and multiple sclerosis share inflammatory machinery. The same cytokines, much of the same signalling. A compound that modulates IL-6 in rheumatoid arthritis cells is acting on a pathway that matters in lupus too.

Why it is still not evidence: autoimmune diseases differ in ways that repeatedly defeat drugs that looked promising elsewhere. Lupus in particular has a long history of therapies that worked in adjacent conditions and failed in trials. Sharing a pathway is a reason to investigate, not a reason to conclude.

Widen from CBG to cannabinoids generally and the lupus literature is small but not empty.

The most relevant work comes from George Washington University and Albert Einstein College of Medicine, published in Experimental Dermatology. Researchers used nano-encapsulated anandamide, an endocannabinoid the body produces itself rather than CBG, and reported reduced inflammatory cytokines in vitro and reduced lesion severity in a mouse model of cutaneous lupus.

There is also a case report in Frontiers in Veterinary Science describing cannabinoid therapy for discoid lupus in a dog. A single-animal case report sits at the bottom of the evidence hierarchy. It is here for completeness.

On symptoms rather than disease activity, a review in Current Rheumatology Reports examined cannabis for rheumatic disease pain in humans and found the literature limited, with study quality a recurring problem.

For context on lupus itself, the Lupus Foundation of America and Yale Medicine both maintain accessible overviews of how the disease works and what current management looks like.

This phrase deserves unpacking, because it does a lot of quiet work in supplement marketing.

In lupus the immune system is not underactive. It is misdirected, producing antibodies against the body’s own tissue. “Boosting” immunity is not the goal, and a product promising to do so is describing something you would not want.

What the research describes is modulation. CBG shifts specific signalling molecules up or down depending on context, which is the distinction the Frontiers review drew above. In the Duesseldorf work that meant less IL-6 and IL-8 and altered antibody output in isolated cells.

Whether that translates into anything meaningful for a person with an autoimmune condition has not been established. That is the honest state of it, and the question is open rather than closed.

Lupus requires medical management. The therapies with human trial evidence behind them are the ones your rheumatologist is working from, including the topical approaches assessed in a systematic review and network meta-analysis in Clinical and Experimental Dermatology.

Nothing here substitutes for that care, and no supplement should be used in place of prescribed therapy. If you are curious about CBG, that conversation belongs with the clinician managing your lupus, particularly because immunosuppressants and antimalarials carry real interaction considerations.

Compounds processed through the same liver enzyme pathways affected by grapefruit can change how other substances are cleared from the body. If you take prescription medication, speak with your prescriber or pharmacist before adding anything new.

CBG appears in Soothe alongside CBD, turmeric, piperine, and myrcene, formulated for everyday tension and physical recovery rather than for any disease state. That is a different question from the one this page is about, and the distinction is deliberate.

Learn about Soothe and how its formula supports the body’s tension and recovery pathways.